ARTV
Artiva Biotherapeutics Inc

224
Loading...
Loading...
News
all
press releases
News Placeholder
Buy Rating Affirmed for Artiva Biotherapeutics Amidst Clinical Advancements and Strong Financials
Analyst Gil Blum from Needham maintained a Buy rating on Artiva Biotherapeutics, Inc. (ARTV Research Report) and keeping the price target at $23...
TipRanks Financial Blog·1y ago
News Placeholder
Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
Artiva Biotherapeutics raised $167 million in its July IPO to advance its innovative cell therapies for autoimmune diseases and cancers. Lead candidate AlloNK, in clinical trials for lupus, is...
Benzinga·1y ago

Latest ARTV News

View

Advertisement. Remove ads.

Advertisement. Remove ads.